Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, despite advancements in guideline-directed medical therapies (GDMTs). A major obstacle to optimal HF management is clinical inertia, defined as the failure of health care providers to initiate or intensify therapy when indicated. This review examined the current state, contributing factors, and strategies for overcoming clinical inertia in HF. Studies have revealed substantial treatment gaps, with sub-optimal prescription rates and dosing of GDMT classes, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, β-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. These treatment gaps persist over time and are associated with increased patient mortality and hospitalizations as well as reduced quality of life. Multiple factors contribute to clinical inertia, including patient-related factors (medication adherence and treatment understanding), provider-related factors (guideline familiarity, concerns regarding side effects, complex treatment decision-making), and health care system-related factors (fragmented care models and quality assessment frameworks). Strategies for overcoming clinical inertia involve patient empowerment through education and shared decision-making, provider education and clinical decision support tools, and redesigning HF care delivery. Specialized HF management systems, multidisciplinary collaboration, remote monitoring, and digital tools can promote guideline adherence. Continuous quality improvement by integrating research and practice is also essential. Addressing clinical inertia requires a multifaceted approach targeting patients, providers, and health care systems. By implementing targeted strategies, health care systems can bridge the evidence-practice gap, optimize GDMT utilization, and ultimately improve outcomes for this vulnerable patient population.

Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, despite advancements in guideline-directed medical therapies (GDMTs). A major obstacle to optimal HF management is clinical inertia, defined as the failure of health care providers to initiate or intensify therapy when indicated. This review examined the current state, contributing factors, and strategies for overcoming clinical inertia in HF. Studies have revealed substantial treatment gaps, with sub-optimal prescription rates and dosing of GDMT classes, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, β-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. These treatment gaps persist over time and are associated with increased patient mortality and hospitalizations as well as reduced quality of life. Multiple factors contribute to clinical inertia, including patient-related factors (medication adherence and treatment understanding), provider-related factors (guideline familiarity, concerns regarding side effects, complex treatment decision-making), and health care system-related factors (fragmented care models and quality assessment frameworks). Strategies for overcoming clinical inertia involve patient empowerment through education and shared decision-making, provider education and clinical decision support tools, and redesigning HF care delivery. Specialized HF management systems, multidisciplinary collaboration, remote monitoring, and digital tools can promote guideline adherence. Continuous quality improvement by integrating research and practice is also essential. Addressing clinical inertia requires a multifaceted approach targeting patients, providers, and health care systems. By implementing targeted strategies, health care systems can bridge the evidence-practice gap, optimize GDMT utilization, and ultimately improve outcomes for this vulnerable patient population.

Purpose: We examined the effectiveness of intervention by orthoptists (ORTS) to 3-year-old infant health examination at Yanai Health Center and Shuto General Hospital to detect visual abnormalities.
Case and methods: Forty-eight children were enrolled in this study. Their parents had wanted to have the children examined by ORTS in the 3-year-old infants health examination in Yanai Health Center or in the Department of Pedeiatrics of Shuto General Hospital from July 2009 to February 2010. At the Yanai Health Center we questioned their parents about the results of their children's visual acuity test at home and other ophthalmological abnormalities. After questioning, we re-examined the visual acuity of the children who did not have enough visual acuity of 10/20 at home with the 2.5 meters visual acuity test. On the other hands, at Shuto General Hospital, we conducted the 2.5 meters visual acuity test with the test of refractive error, ocular alignment and binocular vision. After these ophthalmic examinations, we questioned the parents abour the efficacy of intervention by ORTS in the health examination.
Results: Eight children (16.6%) needed closer ophthalmic examinations. Three children with hyperopias, and one with anisometropic amblyopia were found. The parents recognized the importance of intervention by ORTS in the ophthalmic screen test. The questionnaire survey revealed that almost half of the parents were afraid of there visual acuity test by themselves at home.
Conclusion: We concluded that we find out critical ophthalmic disorder such as refract error which lead to amblyopia by the intervention of ORTS or ophthalmologists in the health screening in Yanai, Yamaguti.